Aardvark Therapeutics, Inc. Common Stock Total Assets
Aardvark Therapeutics, Inc. Common Stock total assets. Based on the latest financial reports, Aardvark Therapeutics, Inc. Common Stock (AARD) holds total assets worth $133.23 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AARD market cap for the company's overall valuation and market capitalisation.
Total Assets of Aardvark Therapeutics, Inc. Common Stock (2022–2024)
Total assets of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024. This chart illustrates how Aardvark Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See AARD stock price and chart for real-time trading data and today's change.
Aardvark Therapeutics, Inc. Common Stock - Asset Composition Analysis
Aardvark Therapeutics, Inc. Common Stock Total Assets Breakdown (December 2024)
Aardvark Therapeutics, Inc. Common Stock total assets breakdown as of December 2024. Aardvark Therapeutics, Inc. Common Stock's total assets of $133.23 Million consist of 95.7% current assets and 4.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 79.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Aardvark Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Aardvark Therapeutics, Inc. Common Stock working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aardvark Therapeutics, Inc. Common Stock's current assets represent 95.7% of total assets in 2024, a decrease from 98.4% in 2022.
- Cash Position: Cash and equivalents constituted 79.5% of total assets in 2024, down from 92.9% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aardvark Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of Aardvark Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Aardvark Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.03 | 31.65 | 7.50 |
| Quick Ratio | 12.03 | 31.65 | 7.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $118.47 Million | $80.05 Million | $8.99 Million |
Aardvark Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Aardvark Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 0.35 |
| Asset Growth Rate (YoY) | 635.6% |
| Total Assets | $77.51 Million |
| Market Capitalization | $26.78 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aardvark Therapeutics, Inc. Common Stock's assets below their book value (0.35x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Aardvark Therapeutics, Inc. Common Stock's assets grew by 635.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual total assets of Aardvark Therapeutics, Inc. Common Stock from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $77.51 Million | +635.64% |
| 2023-12-31 | $10.54 Million | -37.12% |
| 2022-12-31 | $16.76 Million | -- |
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial… Read more